KURA: Ziftomenib leads in acute leukemia with robust growth and pivotal data expected in 2028
Ziftomenib is driving market leadership in acute leukemia with strong commercial uptake and ongoing phase III trials, while darlifarnib advances in solid tumor combinations. The launch of Caspian Therapeutics enables expansion into diabetes, and multiple data updates are expected in Q4.Based on Kur…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.